CEOP/PEB交替化疗用于晚期中、高度恶性非霍奇金淋巴瘤

CEOP/PEB alternating chemotherapy in advanced intermediate and high-grade non-Hodgkin's lymphomas.

作者信息

Abate G, Tafuto S, Romano A, Gailli E, Corazzelli G

机构信息

Divisione di Ematologia Oncologica, Istituto Nazionale Tumori, Napoli, Italy.

出版信息

Haematologica. 1992 Jul-Aug;77(4):322-5.

PMID:1385277

Abstract

BACKGROUND AND METHOD

From February, 1987 to July, 1990, 28 patients (M/F = 16/12; median age = 60.5 yrs) affected by intermediate (22) or high-grade (6) advanced stage (III = 8; IV = 20) NHL were given a median (range 4-10) of 8 cycles of CEOP (Cyclophosphamide, Epirubicin, Vincristine and Prednisone), alternated every 21 days with PEB (Cisplatin, Etoposide, Bleomycin).

RESULTS

Nineteen (68%) pts. achieved a CR, 5 (18%) a PR, and 4 (14%) experienced progressive disease (PD); 11/19 CRs subsequently relapsed within a median (range 3-15) time of 8 mos.. After a follow-up ranging from 6 to 42+ (median 18) mos., the 3-year actuarial overall survival (OS) was 51% and shifted to 18% at 42 mos. After 7-42+ (median 19) mos., 14/19 (73%) Crs were still alive with 63% of them predicted to survive at 3 years. The projected 3-year disease-free survival (DFS) for these pts. after 1-36+ (median 8) mos. was 28%.

DISCUSSION

CEOP/PEB alternating chemotherapy failed to improve the therapeutic results we obtained in a previous study with CEOP alone. Toxicity was moderate, but higher than expected.

摘要

背景与方法

1987年2月至1990年7月，28例（男/女 = 16/12；中位年龄 = 60.5岁）中晚期（Ⅲ期 = 8例；Ⅳ期 = 20例）非霍奇金淋巴瘤（NHL）患者，其中22例为中度、6例为高度，接受了中位（范围4 - 10）8周期的CEOP（环磷酰胺、表柔比星、长春新碱和泼尼松）化疗，每21天与PEB（顺铂、依托泊苷、博来霉素）交替使用。

结果

19例（68%）患者达到完全缓解（CR），5例（18%）部分缓解（PR），4例（14%）疾病进展（PD）；19例CR患者中有11例在中位（范围3 - 15）8个月时复发。经过6至42 +（中位18）个月的随访，3年总生存率（OS）精算值为51%，42个月时降至18%。7至42 +（中位19）个月后，19例CR患者中有14例（73%）仍存活，其中63%预计3年存活。这些患者在1至36 +（中位8）个月后的预计3年无病生存率（DFS）为28%。